These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23807604)

  • 1. The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.
    Fleseriu M
    Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):321-9. PubMed ID: 23807604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
    Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the pharmacotherapy of patients with acromegaly.
    Fleseriu M
    Discov Med; 2014 Jun; 17(96):329-38. PubMed ID: 24979253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological approach to the treatment of acromegaly.
    Ezzat S
    Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future medical treatments for patients with acromegaly.
    Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
    Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of combination medical therapy in the treatment of acromegaly.
    Lim DS; Fleseriu M
    Pituitary; 2017 Feb; 20(1):136-148. PubMed ID: 27522663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
    Ciresi A; Radellini S; Guarnotta V; Giordano C
    BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline treatment in acromegaly: cons.
    Kasuki L; Vieira Neto L; Gadelha MR
    Endocrine; 2014 Jun; 46(2):220-5. PubMed ID: 24504766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
    Chanson P
    Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant and cabergoline combination therapy in acromegaly.
    Bernabeu I; Alvarez-Escolá C; Paniagua AE; Lucas T; Pavón I; Cabezas-Agrícola JM; Casanueva FF; Marazuela M
    Pituitary; 2013 Mar; 16(1):101-8. PubMed ID: 22396133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline treatment in acromegaly: pros.
    Marazuela M; Ramos-Leví A; Sampedro-Núñez M; Bernabeu I
    Endocrine; 2014 Jun; 46(2):215-9. PubMed ID: 24532103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy: options and uses.
    Carmichael JD; Bonert VS
    Rev Endocr Metab Disord; 2008 Mar; 9(1):71-81. PubMed ID: 18163211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
    Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.